U.S.C. homeSearch U.S. Code
U.S. CodeTitle 21Chapter 9— Federal Food, Drug, And Cosmetic ActSubchapter V— Drugs and DevicesPart A— Drugs and Devices

21 U.S.C. § 353a (2026)

Pharmacy compounding

Edition and currency
U.S. Code current through Pub. L. 119-102 (OLRC release point). The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTU.S. Code current through Pub. L. 119-102 (OLRC release point) ACTIVE · 13 IN 5Y cited 1999–2025 39citing cases
At a glance

Courts have cited this section in 39 opinions since 1999, 13 of them in the last five years. The most litigated part is subsection (a) (16 cases).

(a) In generalSections 351(a)(2)(B), 352(f)(1), and 355 of this title shall not apply to a drug product if the drug product is compounded for an identified individual patient based on the receipt of a valid prescription order or a notation, approved by the prescribing practitioner, on the prescription order that a compounded product is necessary for the identified patient, if the drug product meets the requirements of this section, and if the compounding—(1) is by—(A) a licensed pharmacist in a State licensed pharmacy or a Federal facility, or(B) a licensed physician,on the prescription order for such individual patient made by a licensed physician or other licensed practitioner authorized by State law to prescribe drugs; or(2)(A) is by a licensed pharmacist or licensed physician in limited quantities before the receipt of a valid prescription order for such individual patient; and(B) is based on a history of the licensed pharmacist or licensed physician receiving valid prescription orders for the compounding of the drug product, which orders have been generated solely within an established relationship between—(i) the licensed pharmacist or licensed physician; and(ii)(I) such individual patient for whom the prescription order will be provided; or(II) the physician or other licensed practitioner who will write such prescription order.(b) Compounded drug(1) Licensed pharmacist and licensed physicianA drug product may be compounded under subsection (a) if the licensed pharmacist or licensed physician—(A) compounds the drug product using bulk drug substances, as defined in regulations of the Secretary published at section 207.3(a)(4) of title 21 of the Code of Federal Regulations—(i) that—(I) comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding;(II) if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary; or(III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, that appear on a list developed by the Secretary through regulations issued by the Secretary under subsection (c);(ii) that are manufactured by an establishment that is registered under section 360 of this title (including a foreign establishment that is registered under section 360(i) of this title); and(iii) that are accompanied by valid certificates of analysis for each bulk drug substance;(B) compounds the drug product using ingredients (other than bulk drug substances) that comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding;(C) does not compound a drug product that appears on a list published by the Secretary in the Federal Register of drug products that have been withdrawn or removed from the market because such drug products or components of such drug products have been found to be unsafe or not effective; and(D) does not compound regularly or in inordinate amounts (as defined by the Secretary) any drug products that are essentially copies of a commercially available drug product.(2) Definition

For purposes of paragraph (1)(D), the term “essentially a copy of a commercially available drug product” does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product.

(3) Drug productA drug product may be compounded under subsection (a) only if—(A) such drug product is not a drug product identified by the Secretary by regulation as a drug product that presents demonstrable difficulties for compounding that reasonably demonstrate an adverse effect on the safety or effectiveness of that drug product; and(B) such drug product is compounded in a State—(i) that has entered into a memorandum of understanding with the Secretary which addresses the distribution of inordinate amounts of compounded drug products interstate and provides for appropriate investigation by a State agency of complaints relating to compounded drug products distributed outside such State; or(ii) that has not entered into the memorandum of understanding described in clause (i) and the licensed pharmacist, licensed pharmacy, or licensed physician distributes (or causes to be distributed) compounded drug products out of the State in which they are compounded in quantities that do not exceed 5 percent of the total prescription orders dispensed or distributed by such pharmacy or physician.The Secretary shall, in consultation with the National Association of Boards of Pharmacy, develop a standard memorandum of understanding for use by the States in complying with subparagraph (B)(i).
(c) Regulations(1) In general

The Secretary shall issue regulations to implement this section. Before issuing regulations to implement subsections (b)(1)(A)(i)(III), (b)(1)(C), or (b)(3)(A), the Secretary shall convene and consult an advisory committee on compounding unless the Secretary determines that the issuance of such regulations before consultation is necessary to protect the public health. The advisory committee shall include representatives from the National Association of Boards of Pharmacy, the United States Pharmacopoeia, pharmacy, physician, and consumer organizations, and other experts selected by the Secretary.

(2) Limiting compounding

The Secretary, in consultation with the United States Pharmacopoeia Convention, Incorporated, shall promulgate regulations identifying drug substances that may be used in compounding under subsection (b)(1)(A)(i)(III) for which a monograph does not exist or which are not components of drug products approved by the Secretary. The Secretary shall include in the regulation the criteria for such substances, which shall include historical use, reports in peer reviewed medical literature, or other criteria the Secretary may identify.

(d) ApplicationThis section shall not apply to—(1) compounded positron emission tomography drugs as defined in section 321(ii) of this title; or(2) radiopharmaceuticals.(e) “Compounding” defined

As used in this section, the term “compounding” does not include mixing, reconstituting, or other such acts that are performed in accordance with directions contained in approved labeling provided by the product’s manufacturer and other manufacturer directions consistent with that labeling.

(June 25, 1938, ch. 675, § 503A, as added Pub. L. 105–115, title I, § 127(a), Nov. 21, 1997, 111 Stat. 2328; amended Pub. L. 113–54, title I, § 106(a), Nov. 27, 2013, 127 Stat. 598.)Editorial NotesAmendments

2013—Subsec. (a). Pub. L. 113–54, § 106(a)(1), struck out “unsolicited” before “receipt of a valid prescription” in introductory provisions.

Subsec. (b)(1)(A)(i)(III). Pub. L. 113–54, § 106(a)(4), substituted “subsection (c)” for “subsection (d)”.

Subsecs. (c) to (f). Pub. L. 113–54, § 106(a)(2), (3), redesignated subsecs. (d) to (f) as (c) to (e), respectively, and struck out former subsec. (c). Prior to amendment, subsec. (c) read as follows: “A drug may be compounded under subsection (a) of this section only if the pharmacy, licensed pharmacist, or licensed physician does not advertise or promote the compounding of any particular drug, class of drug, or type of drug. The pharmacy, licensed pharmacist, or licensed physician may advertise and promote the compounding service provided by the licensed pharmacist or licensed physician.”

Statutory Notes and Related SubsidiariesEffective Date

Pub. L. 105–115, title I, § 127(b), Nov. 21, 1997, 111 Stat. 2330, provided that: “Section 503A of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 353a], added by subsection (a), shall take effect upon the expiration of the 1-year period beginning on the date of the enactment of this Act [Nov. 21, 1997].”

The 20 cases that cite 21 U.S.C. § 353a most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENThompson v. W. States Med. Ctr., 535 U.S. 357 (2002).
cites § 353a 7×subsections: (a) 3× (c)cited by 274 cases
Where it cites § 353a
“2328 , 21 U. S. C. § 353a, exempts “compounded drugs” from the Food and Drug Administration’s standard drug approval requirements as long as the providers of those drugs abide by several restrictions, including that they refrain from advertising or promoting particular…”
The case’s holding
A regulation prohibiting the advertising of compounded drugs violates the First Amendment if the government can achieve its interests through less restrictive, non-speech-related means.
Later courts cite it for
“if the government could achieve its interests in a manner that does not restrict speech, or that restricts less speech, the government must do so.” · 22 citing courts
2
GREENUnited States v. Caronia, 703 F.3d 149 (2d Cir. 2012).
cites § 353a 3×subsections: (c) 3×cited by 77 cases
The case’s holding
The First Amendment prohibits the government from criminalizing the truthful, non-misleading promotion of an FDA-approved drug for off-label use.
Later courts cite it for
“once fda-approved, prescription drugs can be prescribed by doctors for both fda-approved and -unapproved uses; the fda generally does not regulate how physicians use approved drugs.” · 4 citing courts
3
GREENUnited States v. Bader, 678 F.3d 858 (10th Cir. 2012).
cites § 353a 3×subsections: (a) (a)(2)cited by 59 cases
Where it cites § 353a
“In Medical Center Pharmacy , the court found that subsections (a) and (c) of the FDAMA, 21 U.S.C. § 353a, were severable from the remainder of § 353a; consequently, pharmacies were still obligated to comply with subsection (b)’s requirements for “compounded drugs.”
The case’s holding
A district court forfeiture order is reviewed as a sentencing determination by reviewing legal conclusions de novo and factual findings for clear error.
Later courts cite it for
“we review the district court's forfeiture order as we would any other sentencing determination - that is, we review its legal conclusions de novo and its factual findings for clear error.” · 3 citing courts
4
GREENMed. Ctr. Pharmacy v. Mukasey, 536 F.3d 383 (5th Cir. 2008).
cites § 353a 3×subsections: (a) 2×cited by 34 cases
Where it cites § 353a
“2296 (codified as amended at 21 U.S.C. § 353a (2000)). Explicitly addressing “pharmacy compounding,” FDAMA sought to permit pharmacy compounding by exempting compounded drugs from the FDCA’s new drug approval, adulteration, and mis-branding provisions, but FDAMA simultaneously…”
The case’s holding
Compounded drugs are new drugs under the FDCA but are exempt from approval only when they meet the specific statutory conditions for pharmacy compounding.
Later courts cite it for
“construing the fdca to give the fda authority over compounding would thus not necessarily 'lead to a result so bizarre that congress could not have intended it.” · 1 citing court
5
GREENLiberty Coins v. David Goodman, 748 F.3d 682 (6th Cir. 2014).
cites § 353a 1×cited by 127 cases
Where it cites § 353a
“However, once pharmacies elected to advertise the availability of those compounded drugs to the medical community and to the public at large, they were required to seek FDA approval. The statute was designed to allow for small quantities of unapproved, experimental compounded…”
The case’s holding
A state licensing statute regulating business conduct is subject to rational basis review rather than heightened scrutiny because it regulates economic activity rather than commercial speech.
Later courts cite it for
“whether the plaintiff has established a substantial likelihood or probability of success on the merits of his claim.” · 6 citing courts
6
GREENUnited States v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014).
cites § 353a 2×subsections: (a) 2×cited by 15 cases
Where it cites § 353a
“See 21 U.S.C. § 353a(a). A compounded drug must be produced using certain types of “bulk drug substances,” one of which is “bulk drug substances .”
Later courts cite it for
“would be unnecessary if the fdca did not otherwise regulate the distribution of drugs by licensed physicians.” · 1 citing court
7
GREENUnited States v. Franck's Lab, Inc., 816 F. Supp. 2d 1209 (M.D. Fla. 2011).
cites § 353a 6×subsections: (a) 2× (b)(1)(A) 2×cited by 3 cases
Where it cites § 353a
“40 A FDAMA & Western States In 1997, “in a move the Pharmacies call a reaction to the FDA’s 1992 [Guide] and the FDA characterizes as a confirmation of it, Congress amended the FDCA by enacting the Food And Drug Modernization Act of 1997 (“FDAMA”), Pub.”
8
GREENMed. Ctr. Pharmacy v. Eric Holder, Jr., 634 F.3d 830 (5th Cir. 2011).
cites § 353a 1×cited by 60 cases
Where it cites § 353a
“§§ 301 -399a, but that they are exempt from the FDCA’s adulteration, misbranding, and new-drug-approval provisions if they comply with the conditions set forth in 21 U.S.C. §§ 353a and 360b(a). On remand, the defendant, the Food and Drug Administration (“FDA”), argued that our…”
The case’s holding
An issue that could have been raised on appeal but was not is forfeited and may not be revisited by the district court on remand.
Later courts cite it for
“an issue that could have been but was not raised on appeal is forfeited and may not be revisited by the district court on remand.” · 13 citing courts
9
GREENMed. Ctr. Pharmacy v. Gonzales, 451 F. Supp. 2d 854 (W.D. Tex. 2006).
cites § 353a 3×subsections: (a)cited by 5 cases
Where it cites § 353a
“21 U.S.C. § 353a In 1997, Congress enacted the Food and Drug Administration Modernization Act of 1997 (“FDAMA”).”
Later courts cite it for
“implicitly exempt from the new drug approval process.” · 2 citing courts
10
GREENW. States Med. Ctr. v. Shalala, 69 F. Supp. 2d 1288 (D. Nev. 1999).
cites § 353a 3×subsections: (a) (c)cited by 7 cases
Where it cites § 353a
“BACKGROUND This case involves a First Amendment challenge to Section 503A of the Food and Drug Modernization Act of 1997 (the “Modernization Act”), codified at 21 U.S.C. § 353a (“ § 353a”). The Modernization Act exempts “compounded drugs” from the standard drug approval…”
11
GREENZyla Life Sciences v. Wells Pharma, 134 F.4th 326 (5th Cir. 2025).
cites § 353a 1×cited by 7 cases
Where it cites § 353a
“2296, 2328 (codified as amended at 21 U.S.C. § 353a). And as relevant in this case, in 2013, Congress also crafted an exemption for certain registered compounding facilities.”
The case’s holding
A state law that expressly incorporates federal requirements creates no conflict and is not preempted by the federal statute it mirrors, since parallel regulation does not upset federal enforcement.
Later courts cite it for
“but as the supreme court explained over a century ago, when state law mirrors federal law, it 'recognizes the supremacy of the national law' by 151 no. 24-50149 'conforming to it.” · 2 citing courts
12
GREENWedgewood Vill. Pharmacy v. Drug Enf't Admin., 509 F.3d 541 (D.C. Cir. 2007).
cites § 353a 1×subsections: (a)cited by 15 cases
Where it cites § 353a
“105-399, at 94, as reprinted in 1997 U.S.C.C.A.N. 2880, 2884.”
cites § 353a 2×cited by 5 cases
Where it cites § 353a
“§ 374 (a), the section upon which the FDA did rely in its application for a warrant.”
14
GREENW. States Med. Ctr. v. Shalala, 238 F.3d 1090 (9th Cir. 2001).
cites § 353a 4×subsections: (c) 2× (a)cited by 8 cases
Where it cites § 353a
“CYNTHIA HOLCOMB HALL, Circuit Judge: This appeal requires us to assess the constitutionality of two subsections of the Food and Drug Administration Modernization Act of 1997 (“FDAMA”), 21 U.S.C. § 353a. Subsections §§ 353a(a) and (c) of FDAMA prohibit drug providers from…”
15
GREENAllergan USA, Inc. v. Prescribers Choice, Inc., 364 F. Supp. 3d 1089 (C.D. Cal. 2019).
cites § 353a 1×cited by 5 cases
Where it cites § 353a
“See 21 U.S.C. §§ 353a, 353b ; *1104 16 Cal. Code Regs.”
Later courts cite it for
“the weight of florida law supports” · 2 citing courts
16
GREENMinnesota ex rel. Hatch v. Sunbelt Comm. & Mkt., 282 F. Supp. 2d 976 (D. Minn. 2002).
cites § 353a 1×cited by 5 cases
Where it cites § 353a
“1999) (concerning pre-enforcement challenge to 21 U.S.C. § 353a); see also Thompson v. W.”
17
GREENUnited States v. Conigliaro, 384 F. Supp. 3d 145 (D.D.C. 2019).
cites § 353a 2×subsections: (a)cited by 1 case
Where it cites § 353a
“In its relevant parts, the FDAMA created a safe harbor for compounded drugs, exempting them from the FDCA's "new drug" requirements provided that certain criteria were met, most pertinently, that they be compounded in response to a valid prescription or only in limited…”
Later courts cite it for
“the fda was unable under congressional questioning to articulate a clear line between compounding and drug manufacturing.” · 1 citing court
18
GREENUnited States v. Livdahl, 459 F. Supp. 2d 1255 (S.D. Fla. 2005).
cites § 353a 3×subsections: (f)cited by 1 case
Where it cites § 353a
“In that case, the Court noted that under the Food and Drug Administration Modernization Act of 1997 (FDAMA), codified at 21 U.S.C. § 353a, compounded drugs are exempted from the FDA’s standard drug approval requirements, as long as the providers of those drugs abide be certain…”
19
NO FLAGCommonwealth v. Tap Pharm. Prods., Inc., 36 A.3d 1112 (Pa. Commw. Ct. 2011).
cites § 353a 1×cited by 14 cases
Where it cites § 353a
“2328 , 21 U.S.C. § 353a); JJ Liquormart Inc. v. Rhode Island, 517 U.”
20
GREENCom. v. Tap Pharm. Prods., Inc., 36 A.3d 1112 (Pa. Commw. Ct. 2011).
cites § 353a 1×cited by 2 cases
Where it cites § 353a
“2328 , 21 U.S.C. § 353a); 44 Liquormart Inc. v. Rhode Island, 517 U.”
Later courts cite it for
“medicaid is a joint state-federal funded program for medical assistance in which the federal government approves a state plan (state plan) for the funding of medical services for the needy and then subsidizes a significant portion of the financial obligations the state agreed to assume.” · 2 citing courts

Show all 39 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199920122025

One bar per year. Tallest: 5 cases in 2011. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
5th Cir.5D.D.C.49th Cir.2C.D. Cal.2D.C. Cir.2S.D. Cal.2M.D. Fla.2S.D. Fla.2

The 8 courts with the most citing cases, of 24 courts in all.

By subsection
(a)16 cases
Thompson v. W. States Med. Ctr., 535 U.S. 357 (2002).“2328 , 21 U. S. C. § 353a, exempts “compounded drugs” from the Food and Drug Administration’s standard drug approval requirements as long as the providers of those drugs abide by several restrictions, including that they refrain from advertising or promoting particular…”
Med. Ctr. Pharmacy v. Mukasey, 536 F.3d 383 (5th Cir. 2008).“2296 (codified as amended at 21 U.S.C. § 353a (2000)). Explicitly addressing “pharmacy compounding,” FDAMA sought to permit pharmacy compounding by exempting compounded drugs from the FDCA’s new drug approval, adulteration, and mis-branding provisions, but FDAMA simultaneously…”
United States v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014).“See 21 U.S.C. § 353a(a). A compounded drug must be produced using certain types of “bulk drug substances,” one of which is “bulk drug substances .”
United States v. Bader, 678 F.3d 858 (10th Cir. 2012).“In Medical Center Pharmacy , the court found that subsections (a) and (c) of the FDAMA, 21 U.S.C. § 353a, were severable from the remainder of § 353a; consequently, pharmacies were still obligated to comply with subsection (b)’s requirements for “compounded drugs.”
Wedgewood Vill. Pharmacy v. Drug Enf't Admin., 509 F.3d 541 (D.C. Cir. 2007).“105-399, at 94, as reprinted in 1997 U.S.C.C.A.N. 2880, 2884.”
Showing the top 5 of 16. More in the list view →
(a)(2)1 case
United States v. Bader, 678 F.3d 858 (10th Cir. 2012).
(b)2 cases
Wingate v. Insight Health Corp., 87 Va. Cir. 227 (Roanoke County Cir. Ct. 2013).
Hope Med. Enter., Inc. v. Fagron Compounding Servs., LLC, No. 2:19-cv-07748 (C.D. Cal. July 7, 2020).
(b)(1)1 case
ImprimisRx, LLC v. OSRX, Inc., No. 3:21-cv-01305 (S.D. Cal. Dec. 12, 2023).
(b)(1)(A)1 case
United States v. Franck's Lab, Inc., 816 F. Supp. 2d 1209 (M.D. Fla. 2011).“40 A FDAMA & Western States In 1997, “in a move the Pharmacies call a reaction to the FDA’s 1992 [Guide] and the FDA characterizes as a confirmation of it, Congress amended the FDCA by enacting the Food And Drug Modernization Act of 1997 (“FDAMA”), Pub.”
(b)(1)(D)1 case
Novo Nordisk Inc. v. Brooksville Pharm. Inc., 785 F. Supp. 3d 1123 (M.D. Fla. 2025).
(b)(2)2 cases
Hope Med. Enter., Inc. v. Fagron Compounding Servs., LLC, No. 2:19-cv-07748 (C.D. Cal. July 7, 2020).
Novo Nordisk Inc. v. Brooksville Pharm. Inc., 785 F. Supp. 3d 1123 (M.D. Fla. 2025).
(b)(3)(B)(ii)1 case
Wellness Pharmacy, Inc. v. Azar, No. 2020-3082 (D.D.C. Sept. 21, 2021).
(c)4 cases
United States v. Caronia, 703 F.3d 149 (2d Cir. 2012).
Thompson v. W. States Med. Ctr., 535 U.S. 357 (2002).
W. States Med. Ctr. v. Shalala, 238 F.3d 1090 (9th Cir. 2001).“CYNTHIA HOLCOMB HALL, Circuit Judge: This appeal requires us to assess the constitutionality of two subsections of the Food and Drug Administration Modernization Act of 1997 (“FDAMA”), 21 U.S.C. § 353a. Subsections §§ 353a(a) and (c) of FDAMA prohibit drug providers from…”
W. States Med. Ctr. v. Shalala, 69 F. Supp. 2d 1288 (D. Nev. 1999).“BACKGROUND This case involves a First Amendment challenge to Section 503A of the Food and Drug Modernization Act of 1997 (the “Modernization Act”), codified at 21 U.S.C. § 353a (“ § 353a”). The Modernization Act exempts “compounded drugs” from the standard drug approval…”
(c)(1)1 case
Wellness Pharmacy, Inc. v. Azar, No. 2020-3082 (D.D.C. Sept. 21, 2021).
(f)1 case
United States v. Livdahl, 459 F. Supp. 2d 1255 (S.D. Fla. 2005).“In that case, the Court noted that under the Food and Drug Administration Modernization Act of 1997 (FDAMA), codified at 21 U.S.C. § 353a, compounded drugs are exempted from the FDA’s standard drug approval requirements, as long as the providers of those drugs abide be certain…”

Show all 39 citing cases (list view) →

Enactment and amendments
(June 25, 1938, ch. 675, § 503A, as added Pub. L. 105–115, title I, § 127(a), Nov. 21, 1997, 111 Stat. 2328; amended Pub. L. 113–54, title I, § 106(a), Nov. 27, 2013, 127 Stat. 598.)
Amendment years (notes): 2013
Versions

Edition shown: U.S. Code current through Pub. L. 119-102 (OLRC release point). Syfert holds no earlier or later version of this section.

U.S.C. Home  |  Search U.S. Code  |  Search cases for this section  |  syfert.com